{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:31:18Z","timestamp":1764333078833,"version":"build-2065373602"},"reference-count":34,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006484","name":"AbbVie (Germany)","doi-asserted-by":"publisher","award":["Nagelpsoriasis Projekt"],"award-info":[{"award-number":["Nagelpsoriasis Projekt"]}],"id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Patients with psoriatic arthritis (PsA) often develop joint symptoms years after their initial diagnosis of psoriasis disease; therefore, dermatologists should test for and detect PsA early. In this study, we focused on patients with psoriasis with both nail and joint disease being treated with tumor necrosis factor-\u03b1 inhibitors by dermatologists. We performed a noninterventional, prospective, multicenter, and open-label study to evaluate the effectiveness of adalimumab, etanercept, or infliximab over 24 months of continuous therapy in patients with moderate to severe plaque-type psoriasis (Pso) and PsA. Disease assessments with the Psoriasis Area and Severity Index, Nail Psoriasis Severity Index (NAPSI), joint assessment, Dermatology Life Quality Index (DLQI), and Health Assessment Questionnaire (HAQ) instruments were performed every 3 months for the first year and twice annually thereafter. The cohort included 100 patients with Pso, nail psoriasis, and PsA. A significant reduction of NAPSI was observed 3 months after therapy initiation compared with the baseline (mean \u00b1 SD, 22.9 \u00b1 17.8 vs. 33.8 \u00b1 21.4; p &lt; 0.001). Similarly, the mean \u00b1 SD number of both tender and swollen joints decreased significantly within the first 3 months of treatment, from 10.8 \u00b1 11.5 to 6.4 \u00b1 10.3 (p &lt; 0.001) and from 6.4 \u00b1 9.5 to 3.1 \u00b1 7.2 (p &lt; 0.001), respectively. Additionally, the distal interphalangeal joint involvement improved throughout the observation time, and DLQI and HAQ scores decreased. Improvements in control of skin, nail, and joint symptoms were seen, as well as in patients\u2019 quality of life and functionality. Dermatologists have an important role not only in PsA diagnosis but also in PsA long-term care.<\/jats:p>","DOI":"10.3390\/jpm11111083","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T21:40:21Z","timestamp":1635198021000},"page":"1083","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of TNF-\u03b1 Inhibitors on Nail Psoriasis and Psoriatic Arthritis\u2014Real-World Data from Dermatology Practice"],"prefix":"10.3390","volume":"11","author":[{"given":"Georgios","family":"Kokolakis","sequence":"first","affiliation":[{"name":"Psoriasis Research and Treatment Center, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 10117 Berlin, Germany"},{"name":"Department of Dermatology, Venereology and Allergology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Sabat","sequence":"additional","affiliation":[{"name":"Psoriasis Research and Treatment Center, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 10117 Berlin, Germany"},{"name":"Interdisciplinary Group of Molecular Immunopathology, Dermatology\/Medical Immunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imma","family":"Fischer","sequence":"additional","affiliation":[{"name":"Biostatistik\u2014T\u00fcbingen, 72070 Tuebingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Gomis-Kleindienst","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co. KG, 65189 Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Fritz","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co. KG, 65189 Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd-R\u00fcdiger","family":"Burmester","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ohrndorf","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2004.06.013","article-title":"Diagnosis and treatment of psoriatic arthritis","volume":"52","author":"Mease","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ocampo, D.V., and Gladman, D. (2019). Psoriatic arthritis. F1000Research, 8.","DOI":"10.12688\/f1000research.19144.1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2217\/imt-2020-0292","article-title":"Immunotherapy in psoriasis","volume":"13","author":"Landeck","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-Guideline on the systemic treatment of psoriasis vulgaris-Update Apremilast and Secukinumab-EDF in cooperation with EADV and IPC","volume":"31","author":"Nast","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: A European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ohrndorf, S., Glimm, A.M., Ammitzboll-Danielsen, M., Ostergaard, M., and Burmester, G.R. (2021). Fluorescence optical imaging: Ready for prime time?. RMD Open, 7.","DOI":"10.1136\/rmdopen-2020-001497"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/jdv.14741","article-title":"Consensus on the management of patients with psoriatic arthritis in a dermatology setting","volume":"32","author":"Gisondi","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e13283","DOI":"10.1111\/dth.13283","article-title":"How does the joint dermatology-rheumatology clinic benefit both patients and dermatologists?","volume":"33","author":"Theodorakopoulou","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: Focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncprheum0987","article-title":"New insights into the pathogenesis and genetics of psoriatic arthritis","volume":"5","author":"Nograles","year":"2009","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00281-021-00848-x","article-title":"Navigating the diverse immune landscapes of psoriatic arthritis","volume":"43","author":"Ritchlin","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00281-019-00742-7","article-title":"T cell pathology in skin inflammation","volume":"41","author":"Sabat","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_15","first-page":"886","article-title":"Measuring health status in psoriatic arthritis: The Health Assessment Questionnaire and its modification","volume":"22","author":"Blackmore","year":"1995","journal-title":"J. Rheumatol."},{"key":"ref_16","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10067-011-1787-1","article-title":"Relationship between psoriatic arthritis and moderate-severe psoriasis: Analysis of a series of 166 psoriatic arthritis patients selected from a hospital population","volume":"31","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"adv00214","DOI":"10.2340\/00015555-3545","article-title":"Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy","volume":"100","author":"Kokolakis","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11926-019-0866-1","article-title":"Psoriatic Arthritis: Newer and Older Therapies","volume":"21","author":"Chao","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: A systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10067-016-3319-5","article-title":"Psoriatic nail involvement and its relationship with distal interphalangeal joint disease","volume":"35","author":"Lai","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/bjd.13272","article-title":"Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis","volume":"171","author":"Langenbruch","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1136\/annrheumdis-2014-205302","article-title":"Comprehensive disease control (CDC): What does achieving CDC mean for patients with rheumatoid arthritis?","volume":"74","author":"Emery","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","first-page":"391","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: Applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines","volume":"63","author":"Mease","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1756-185X.12283","article-title":"Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone?","volume":"18","author":"Tezel","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/exd.12265","article-title":"Jakpot! New small molecules in autoimmune and inflammatory diseases","volume":"23","author":"Ghoreschi","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s13555-021-00523-x","article-title":"Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management","volume":"11","author":"Hadeler","year":"2021","journal-title":"Dermatol. Ther."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/11\/1083\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:04Z","timestamp":1760167384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/11\/1083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["jpm11111083"],"URL":"https:\/\/doi.org\/10.3390\/jpm11111083","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2021,10,25]]}}}